Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.01 EPS

Kymera Therapeutics (NASDAQ:KYMR) announced its quarterly earnings data on Thursday. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01, Briefing.com reports. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The company’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.90) EPS.

Kymera Therapeutics Trading Down 0.7 %

KYMR stock traded down $0.34 during midday trading on Friday, reaching $45.83. The company had a trading volume of 149,574 shares, compared to its average volume of 596,110. Kymera Therapeutics has a 1 year low of $9.60 and a 1 year high of $53.27. The company has a 50 day moving average of $47.06 and a two-hundred day moving average of $40.57. The company has a market capitalization of $2.83 billion, a P/E ratio of -19.03 and a beta of 2.21.

Analyst Ratings Changes

KYMR has been the subject of several analyst reports. Truist Financial reissued a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday. Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Wells Fargo & Company increased their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Finally, Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $48.92.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.